United States securities and exchange commission logo




                                                                                
                             February 7, 2024

       Paul Mellett
       Chief Financial Officer
       Enanta Pharmaceuticals, Inc.
       500 Arsenal Street
       Watertown
       MA
       02472

                                                        Re: Enanta 
Pharmaceuticals, Inc.
                                                            Form 10-K for 
Fiscal Year Ended September 30, 2023
                                                            File No. 001-35839

       Dear Paul Mellett:

              We have limited our review of your filing to the financial 
statements and related
       disclosures and have the following comment.

              Please respond to this letter within ten business days by 
providing the requested
       information or advise us as soon as possible when you will respond. If 
you do not believe
       the comment applies to your facts and circumstances, please tell us why 
in your response.

                                                        After reviewing your 
response to this letter, we may have additional comments.

       Form 10-K for Fiscal Year Ended September 30, 2023

       Item 7. Management's Discussion and Analysis of Financial Condition and 
Results of Operations
       Results of Operations
       Research and development expenses, page 57

   1.                                                   You disclose that you 
do not report information regarding costs incurred for your early-
                                                        stage research and drug 
discovery programs on a project-specific basis. Please revise your
                                                        future filings to 
address the following:
                                                            Revise to clarify 
the extent to which you track these costs on a project-specific basis
                                                            or disease-specific 
basis.
                                                            To the extent you 
do track this information, revise your future filings to break out
                                                            clinical research 
and development program expenses by product candidate (i.e. EDP-
                                                            938, EDP-323). 
Alternatively, break out the Virology expense line item by disease
                                                            target (i.e. RSV, 
HBC, COVID-19).
                                                            If you do not track 
expenses at a more granular level, revise to explain why not.
 Paul Mellett
Enanta Pharmaceuticals, Inc.
February 7, 2024
Page 2
                For all unallocated expenses, revise to provide a breakdown by 
nature of expense.

       In closing, we remind you that the company and its management are 
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, 
comments, action or
absence of action by the staff.

       Please contact Tracie Mariner at 202-551-3744 or Vanessa Robertson at 
202-551-3649
with any questions.



FirstName LastNamePaul Mellett                                Sincerely,
Comapany NameEnanta Pharmaceuticals, Inc.
                                                              Division of 
Corporation Finance
February 7, 2024 Page 2                                       Office of Life 
Sciences
FirstName LastName